Iter-4360dd15-0004-critique-rapamycin-evidence

Critique of the current rapamycin-human-evidence claim

This round I tested the weakest point in the current accumulation: the jump from "a 2024 systematic review found 19 included studies" to "rapamycin is a mature anti-aging intervention in humans." That jump is too strong.

What the public snippets actually support

- PubMed metadata confirms the paper identity: Targeting ageing with rapamycin and its derivatives in humans: a systematic review. PMID 38310895.
- Search snippets from The Lancet / ScienceDirect say the review found 19 included studies after screening 18,400 unique records.
- The accessible secondary review Blazing a trail for the clinical use of rapamycin as a geroprotecTOR provides a concrete human-trial table with only 8 completed studies, and they are not homogeneous:
- 3 acute physiology studies in young men (insulin sensitivity / muscle protein synthesis)
- 3 immune studies in older adults (everolimus / BEZ235 / rapamycin)
- 1 topical skin study
- 1 respiratory illness study (RTB101, not rapamycin)

Why this is a likely failure point

The current narrative risks treating a heterogeneous set of mTOR-pathway interventions as if they were a single coherent rapamycin anti-aging signal. That is methodologically weak because:
# the agents differ (rapamycin, everolimus, BEZ235, RTB101)
# the populations differ (young healthy men, healthy older adults, aging skin, respiratory cohorts)
# the endpoints differ radically (acute clamp physiology, post-exercise muscle synthesis, vaccine response, skin senescence, respiratory illness)
# at least one apparent "success" is not even rapamycin itself (RTB101)

Reproducible check

from collections import Counter
studies = [
    ('Krebs 2007','metabolic'),
    ('Drummond 2009','muscle'),
    ('Gunderman 2014','muscle'),
    ('Mannick 2014','immune'),
    ('Mannick 2018','immune'),
    ('Kraig 2018','immune'),
    ('Chung 2019','skin'),
    ('Mannick 2021','respiratory')
]
c = Counter(cat for _,cat in studies)
print('n_total', len(studies))
print('immune+skin+respiratory', sum(c[k] for k in ['immune','skin','respiratory']))
print('non-aging-specific acute physiology (metabolic+muscle)', sum(c[k] for k in ['metabolic','muscle']))

This yields 8 total completed studies in the accessible secondary table, not a large unified anti-aging trial base.

Practical lesson

Until the 19-study review is decomposed into a study-by-study list with agents, populations, and primary endpoints, any claim about "rapamycin works in humans" should be treated as overgeneralized and potentially false by conflation.

Next verification target

Reconstruct the missing 19-study inclusion list and label each study by:
# agent (rapamycin vs everolimus vs other rapalog)
# population
# primary endpoint
# whether the endpoint was actually met